Scott Galloway argues that GLP-1 drugs (like Ozempic) will have a greater impact on people's lives and ultimately create more shareholder value than artificial intelligence. When asked, individuals who use both would likely give up AI before their GLP-1 medication, highlighting its profound personal impact.

While AI dominates headlines, GLP-1 drugs could have a more profound and immediate impact on society. They address the core mechanism of desire ("wanting less"), with applications for obesity, addiction, and compulsive behaviors that could fundamentally reshape public health and daily life.

Weight-loss drugs like Ozempic have moved from a niche medical treatment to a mainstream phenomenon, with new data showing 15.2% of all American women are now taking them. This rapid, large-scale adoption signifies a major public health shift that will have downstream effects on the food, fitness, and healthcare industries.

The widespread adoption of GLP-1 drugs for obesity, projected to reach 25 million U.S. users, will significantly reduce food, soda, and alcohol consumption. This presents a material, long-term revenue threat to consumer-facing industries like fast food, snack companies, and even casinos, forcing investors in those sectors to adjust their models.

Scott Galloway argues GLP-1 drugs (like Ozempic) will have a greater societal impact than AI. By tackling obesity, they could halve U.S. healthcare costs, help solve the deficit, and even curb addictions, making them a profoundly transformative technology.

Financial analysts suggest weight loss drugs will have societal and economic ripple effects as transformative as the smartphone. The impact extends far beyond healthcare, poised to disrupt industries from food and retail to airlines, which may see reduced fuel costs due to a lighter population.

The widespread adoption of GLP-1 therapies is projected to decrease total U.S. calorie consumption by 1.6% by 2035. This second-order effect will create significant disruption and headwinds for industries reliant on consumer food purchasing, including the CPG, retail, and restaurant sectors.

The conversation frames GLP-1 weight-loss drugs not merely as a healthcare breakthrough but as a potential moonshot for the national economy. A mass government rollout could drastically reduce healthcare costs, improve mental health, and boost productivity, representing a powerful tool for social and economic policy with far-reaching ramifications.

Andrew Huberman predicts GLP-1 drugs, accessed via compounding pharmacies and gray markets, will become so ubiquitous that being a healthy weight will no longer signal extreme discipline. This mirrors how auto loans and leases made luxury cars accessible to the masses, changing their social signaling value.